You are here

Article Text

Article menu
Download PDFPDF
Eular news
News from EULAR
  1. EULAR Communications,
  2. Yuliia Caliskan
  1. Communications, European Alliance of Associations for Rheumatology, Zurich, Switzerland
  1. Correspondence to Dr Yuliia Caliskan, Communications, European Alliance of Associations for Rheumatology, Zurich 8802, Switzerland; yuliia.caliskan{at}eular.org

https://doi.org/10.1136/ard-2023-225123

Statistics from Altmetric.com

    The latest recommendations from the European Alliance of Associations for Rheumatology

    • European Alliance of Associations for Rheumatology (EULAR) recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update: EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update %7C Annals of the Rheumatic Diseases(bmj.com)

    • 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice: https://ard.bmj.com/content/early/2024/02/05/ard-2023-224771

    For recommendations relevant to people with RMDs, EULAR provides a lay summary version in English and calls on all interested organisations to disseminate them and encourage the translation into their own language:

    • EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update: Lay Summary.pdf(eular.org)

    Find more EULAR recommendations at EULAR %7C Recommendations and initiatives

    Registration for EULAR 2024 Congress in Vienna is open!

    ‘The EULAR 2024 Congress is taking place in the beautiful city of Vienna, Austria, where we will foster knowledge sharing, innovation, and striving for …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • X @eular_org

    • Contributors YC created and edited the content. Dr Julia Rautenstrauch was responsible for editing and the overall content as a guarantor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.